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Abstract 
We previously identified Hop as over expressed in invasive pancreatic cancer cell 
lines and malignant tissues of pancreatic cancer patients, suggesting an important role 
for Hop in the biology of invasive pancreatic cancer. Hop is a co-chaperone protein 
that binds to both Hsp70/Hsp90. We hypothesised that by targeting Hop, signalling 
pathways modulating invasion and client protein stabilisation involving Hsp90-
dependent complexes may be altered.  
In this study, we show that Hop knockdown by small interfering (si)RNA reduces the 
invasion of pancreatic cancer cells, resulting in decreased expression of the 
downstream target gene, matrix metalloproteinases-2 (MMP-2). Hop in conditioned 
media co-immunoprecipitates with MMP-2, implicating a possible extracellular 
function for Hop. Knockdown of Hop expression also reduced expression levels of 
Hsp90 client proteins, HER2, Bcr-Abl, c-MET and v-Src. Furthermore, Hop is 
strongly expressed in high grade PanINs compared to lower PanIN grades, displaying 
differential localisation in invasive ductal pancreatic cancer, indicating that the 
localisation of Hop is an important factor in pancreatic tumours.  
Our data suggests that the attenuation of Hop expression inactivates key signal 
transduction proteins which may decrease the invasiveness of pancreatic cancer cells 
possibly through the modulation of Hsp90 activity. Therefore, targeting Hop in 
pancreatic cancer may constitute a viable strategy for targeted cancer therapy.  
 
Key words: Hop/STIP1/STI1 (Hsp70/Hsp90-organising protein), pancreatic cancer, 
immunohistochemistry, in vitro invasion, MMP-2.  
 
Abbreviations: PanIN- pancreatic intraepithelial neoplasia, IHC-
immunohistochemistry, 17AAG-17-allylamino-17 demethoxygeldanamycin 
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1.0 Introduction 
 
Pancreatic adenocarcinoma is one of the most lethal and poorly understood human 
malignancies. The 5-year survival rate is between 1-4% [1], mainly due to the lack of 
effective therapies. Conventional treatment used to treat pancreatic cancer such as 
surgery, chemotherapy, radiation or combinations of these have had very little effect 
on the overall survival of this disease [2].  
Hop (Hsp70/Hsp90-organising protein) or STIP1 (Stress-induced phosphoprotein 1) 
mediates the association, and forms a physical complex with the molecular 
chaperones heat shock proteins (Hsp) Hsp70 and Hsp90 [3, 4] which is dependent on 
the hydrolysis of ATP and ADP/ATP exchange. Hop optimises the functional co-
operation between Hsp70 and Hsp90 which requires highly co-ordinated interactions 
for the folding and conformational regulation of a variety of proteins [5]. The 
molecular chaperone complex of Hop, Hsp70 and Hsp90 is involved in the folding 
and maturation of key regulatory proteins involved in cell viability [6], such as steroid 
hormone receptors, transcription factors and kinases (some of which are involved in 
cancer progression). The role of Hop in tumour progression is not fully elucidated; 
however, Hop has been shown to be over expressed in colonic carcinoma cells [7] and 
in hepatocellular carcinoma (HCC) [8]. Hop is secreted by and shown to induce 
proliferation in glioma tumour cells through MAPK and P13K pathways [9]. Hop has 
also been implicated in the controlled death process. Bredemeyer et al. [10] confirmed 
Hop as a substrate of the apoptotic protease granzyme B (GzmB), as Hop was directly 
cleaved by GzmB in vitro and in cells undergoing GzmB-induced apoptosis. 
Expression of the two cleavage fragments of Hop did not induce cell death; however, 
cleavage of Hop by GzmB did result in loss of Hop function in vitro.  
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There is increasing evidence that heat shock proteins play an important role in the 
development, maintenance and progression of cancer [11]. Heat shock proteins such 
as, Hsp90 and Hsp70 have previously been implicated in pancreatic cancer [12, 13]. 
Hsps are highly conserved molecules, which protect cells from various environmental 
damages, including stress and carcinogenesis [14] and are activated by the ubiquitin-
proteasome pathway. The covalent attachment of ubiquitin to protein regulates a 
number of cellular processes including responses to stress. This process is responsible 
for selective targeting of proteins for degradation. The induced Hsps play roles as 
cellular chaperones, and many modulate apoptotic pathways, particularly those 
involving mitochondria, conferring protection from stressful stimuli including 
chemotherapeutic agents [15]. Hsp90 client proteins include mutated p53, Bcr-Abl, 
Raf-1, Akt, HER2 (ErbB2) and hypoxia inducible factor-1alpha (HIF-1alpha) [16]. 
We previously profiled Hop expression in an in vitro pancreatic cancer cell line 
invasion model and pancreatic tumour tissue specimens [17]. In the present study, we 
hypothesised that modulation of Hop expression could alter invasion and affect the 
activity of Hsp90 and its client proteins; suppression of Hop by siRNA reduced 
invasion through decreased expression of MMP-2. We further show that modulation 
of Hop alters the activities of representative Hsp90 client proteins HER2, Bcr-Abl, c-
MET and v-Src. This study reports that Hop is likely to play a role in invasion of 
pancreatic cancer cells, and possibly contribute to the highly aggressive metastatic 
phenotype of pancreatic cancer. In addition our findings support Hop as a potential 
therapeutic target for the treatment of pancreatic cancer. 
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2. Materials and methods 
2.1 Cell lines 
The human pancreatic cell lines Panc-1, SW1990, Capan-1, MiaPaCa-2 (ATCC, 
USA), HPAC (DSMZ, Germany) and BxPc-3 (ECACC, UK) were used in this study. 
Clone #3 and Clone #8 were previously isolated by single cell dilution from 
MiaPaCa-2 in this laboratory [18]. Cells were maintained in a humidified atmosphere 
containing 5 % CO2 at 37
o C in Dulbecco’s modified Eagles medium (DMEM) 
supplemented with 5% (v/v) fetal bovine serum (Sigma-Aldrich). All cell lines were 
free from Mycoplasma as tested with the indirect Hoechst staining method. 
2.2 Invasion assays 
Invasion assays were performed as previously described [19]. Briefly, matrigel was 
diluted to 1 mg/ml in serum free DMEM. 100 l of matrigel was coated on each 
Boyden chamber insert (Falcon) (8.0 m pore size), in a 24-well plate (Costar) and 
incubated overnight at 4o C. The matrigel was allowed polymerise at 37o C for 1 hr, 
then washed with DMEM. 100 l of complete DMEM was added to the wells and 
1x105/100 l cells were then seeded onto the insert. 500 l of complete DMEM was 
added into the underside of the well. After 24 hours incubation, the inside of the insert 
was wiped with a wet cotton swab. The under surface was gently rinsed with PBS and 
stained with 0.25 % (w/v) crystal violet for 10 minutes, rinsed again with sterile water 
and allowed to dry. The inserts were then viewed under the microscope and the 
number of cells per field in 10 random fields, were counted at 200× magnification. 
The average number of cells per field was then multiplied by a factor of 140 (growth 
area of membrane/field area viewed at 200× magnification (calibrated using a 
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microscope graticule)) to determine the total number of invading cells. Experiments 
were performed in triplicate. 
 
2.3 Immunoblotting 
Whole protein was extracted from cell lysates using 1x lysis buffer (50 mM Tris-Cl, 
150 mM NaCl, and 0.5% (v/v) NP-40). Lysates were centrifuged for 15 min at 16,000 
x g at 4o C. Protein concentrations were determined using the Bio-Rad Bradford 
protein assay according to manufacturer’s instructions (Bio-Rad). 25 g of protein 
was separated by 7.5 and 10% (w/v) SDS-PAGE gels under reducing conditions. 
Proteins were transferred to nitrocellulose membrane (Amersham). Membranes were 
blocked at 4 oC overnight in TBS (25mM Tris-HCl, pH 7.4, 150mM NaCl, 2.7mM 
KCl) containing 5% (w/v) lowfat milk powder. Membranes were probed with 
antibodies Hop/STIP1 (ab56873, Abcam), Hsp70, Hsp90 (#4872, #4875, Cell 
Signaling), Bcr-Abl (#2862, Cell Signaling), HER2 (#2165, Cell Signaling), c-MET 
(sc-10, Santa Cruz), v-Src (OP07T, Merck) and β-actin (Sigma). Membranes were 
washed 3x for 5 min with PBS-Tween-20 (0.5% v/v) and incubated with secondary 
antibodies, anti-mouse (Sigma) and anti-rabbit (Cell Signaling) for 1 hr at RT and 
washing step repeated. Detection was performed with Luminol reagent (Santa Cruz 
Biotechnology).  
 
2.4 siRNA transient transfections                                                                                                      
Three pre-designed siRNAs (Ambion) were chosen for each of the protein/gene 
targets and transfected into cells. Hop/STIP1 siRNA targets (Ambion, #106197, 
#106196, and #106195). For each set of siRNA transfections carried out, a control 
(non-transfected) and a scrambled (SCR) (Ambion, # 17010) were used. siRNA 
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experiments were set up using 2 l NeoFx (Ambion, AM4511), to transfect 30 nM 
siRNA at a cell density of 3x105 /ml in a 6-well plate. Transfection medium was 
removed after 24 hours and replaced with fresh growth medium. The transfected cells 
were collected at 72 and 96 hrs for immunoblotting and assayed for changes in 
invasion capacity at 72 hrs using the in vitro invasion assay (as previously described). 
 
2.5  Zymography 
Pancreatic cancer cells (∼70-80% confluent) were washed and replenished with 
serum-free DMEM for 48 hrs. Cells were then pretreated with various concentrations 
of 17-AAG (Merck) for 24 hrs vs control conditioned media in serum-free conditions 
for 72 hrs. The volume of conditioned medium was normalised by cell number. CM 
samples were denatured, run on 10% (w/v) gelatin gels (Invitrogen Life 
Technologies) and renatured in zymogram renaturing buffer and developed in 
zymogram developing buffer (Invitrogen). Gels were stained with 0.5% (w/v) 
coomassie blue, destained in a solution containing 10% (v/v) methanol and 7.5% (v/v) 
acetic acid. Zones of gelatinolytic activity were detected as clear bands against a blue 
background.  
 
2.6  Immunoprecipitation (IP) 
Protein from conditioned media was lysed in buffer (4% w/v CHAPS, 7 M urea, 2 M 
thiourea, 10 mM Tris-HCL, 5 mM magnesium acetate pH 8.5) and incubated with 200 
µg of Hop (sc-136082, Santa Cruz) or control mouse IgG, at 4 0C, shaking, for 30 
min. In order to precipitate the antibody/antigen complex, 50 µl of packed Protein-L 
agarose beads (#20512, Pierce) were added and samples incubated overnight on a 
rocking platform at 4 0C. Samples were then centrifuged at 16,000 x g for 25 sec and 
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pellets washed with IP wash buffer x3. Samples were centrifuged gently after each 
wash step. Supernatants were removed and pellets resuspended in 50 µl denaturing 
buffer and boiled at 95 0C for 5 min. Denatured samples were then centrifuged at 
16000 x g for 3 min and supernatant collected and stored at -20 0C. 
Immunoprecipitates were separated on 7.5% (w/v) SDS PAGE gels and probed with 
Hsp90 (#4875, Cell Signaling), Hop/STIP1 (ab56873, Abcam) and MMP-2 (IM53, 
Merck) antibodies. 
 
2.7  Immunohistochemistry 
Formalin-fixed paraffin-embedded pancreatic tumour 4-µm sections of tissue blocks 
were cut using a microtome, mounted onto poly-l-lysine coated slides and dried 
overnight at 37 oC. Slides were stored at room temperature until required. Briefly, the 
slides were immunohistochemically stained using primary antibodies specific for 
Hop/STIP1 (ab56873, Abcam). After deparaffinisation and rehydration, the slides 
were subjected to an antigen retrieval step consisting of 20-minute incubation in pH 
9.0 buffer (Target Retrieval, Dako) in a 95°C water bath followed by cooling to room 
temperature. Staining was performed using an automated staining apparatus for IHC 
(Autostainer, Dako) according to the manufacturer’s guidelines. The proper positive 
and negative controls were processed at the same time. The slides were counterstained 
with haematoxylin, dehydrated in graded alcohols and mounted (DPX, Sigma). 
Scoring and interpretation was carried out by consultant pathologist NS. 
 
2.8 Statistical Analysis                                                                                                                        
Student’s t-tests (two-tailed, two-sample unequal variance) were used to analyse 
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differences in protein expression between comparisons. A p-value ≤ 0.05*, ≤ 0.01** 
and ≤ 0.005*** was considered statistically significant. 
 
 
3.0 Results 
3.1 Hop is associated with invasive pancreatic carcinoma 
We previously identified Hop/STIP1 by 2D DIGE followed by MALDI-TOF MS as 
2-fold more abundant in Clone #3, a highly invasive sub-population of the human 
pancreatic cancer cell line MiaPaCa-2, compared to the low invasive Clone #8 [17]. 
In this study, we examined constitutive Hop expression in a panel of seven human 
pancreatic cancer cell lines by Western immunoblot (Fig 1A) and studied its 
expression with the invasive status of the cell lines (Fig 1 B&C). All cell lines express 
Hop but higher abundance of Hop was observed in the more invasive cell lines. 
 
3.2 Hop, as a novel inducer of pancreatic cancer cell invasion 
To determine whether loss of Hop affects the ability of cells to invade in vitro, we 
compared the ability of BxPc-3 and Panc-1 (high Hop expression) human pancreatic 
cancer cell lines to invade through matrigel-coated Boyden chambers post Hop-
siRNA transfection. As Hop-siRNA (2) and (3) were more effective at Hop 
knockdown (Fig 5), we used these siRNAs for further studies. Invasion of Panc-1 
cells was reduced by 50% (p=0.0005) using Hop-siRNA (2) and by 50% (p=0.003) 
with Hop-siRNA (3) (Fig 2A). Invasion of BxPc-3 transfected cells were reduced by 
51% (p=0.002) using Hop-siRNA (2) and by 46% (p=0.002) in the case of Hop-
siRNA (3) (Fig 2B).  
 
3.3 Matrix metalloproteinases down regulated as a result of Hop knockdown  
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We further investigated how knockdown of Hop using siRNA could affect invasion. 
Previously, secretion of HSP90α into the extracellular matrix surrounding tumour 
cells was reported to assist the activation of MMP-2 as well as contributing to tumour 
cell invasiveness [20, 21]. We show that Hop is found in the conditioned medium of 
both Panc-1 and BxPc-3 cells and therefore may possibly have an extracellular role in 
Hsp90 client protein activation (Fig 3A). Inhibition of Hop by Hop-siRNA 
transfection reduced the expression of MMP-2 in both Panc-1 and BxPc-3 as 
determined by immunoblotting (Fig 3B).  
 
3.4 Hop co-immunoprecipitates with MMP-2 
Our findings suggest that Hop may act as an extracellular protein; we confirmed that 
Hop co-immunoprecipitates with MMP-2 in BxPc-3 conditioned media, showing a 
direct interaction between these proteins (Fig 4A), suggesting that Hop may be acting 
as an extracellular co-chaperone to Hsp90, in turn activating MMP-2. Our studies 
support this suggestion as Hop, p23 and Hsp90 were found in the conditioned media 
of HT-1080 cells, showing a direct interaction between these proteins extracellularly 
[21]. Inhibition of Hop may have affected MMP-2 expression and activity through 
altering the activity of extracellular Hsp90. A study by Tsutsumi et al. [22] using the 
non cell-permeable Hsp90 inhibitor, DMAG-N-oxide, reduced in vitro tumour cell 
invasion and migration and decreased melanoma lung metastasis in vivo. The 
monoclonal antibody (mAb) directed against Hsp90, mAb 4C5, inhibited melanoma 
cell invasion and significantly reduced metastasis in vivo by binding to surface Hsp90 
as it is not internalised, further indicating an extracellular role for Hsp90 [23]. We 
also show that the specific Hsp90 inhibitor, geldanamycin (17-AAG) at 0.1 µM and 1 
µM blocks MMP-2 and MMP-9 [24] activation as revealed by zymography (Fig 4B). 
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Invasion in the highly invasive Panc-1 and BxPc-3 cells lines was also reduced at 1 
µM 17-AAG (Fig 4C & D), proliferation and cell survival at this concentration was 
not effected (data not shown).  
 
3.5 Role of Hop as an Hsp90/Hsp70 co-chaperone protein – silencing of Hop 
alters expression of downstream Hsp90 client proteins 
Hsp90 client proteins play important roles in the regulation of the cell cycle, cell 
growth, cell survival, apoptosis, and tumour progression. To investigate whether Hop 
could serve as a therapeutic target in pancreatic cancer, we used Hop-siRNA to 
knockdown Hop expression in three invasive human pancreatic cancer cell lines: 
Clone #3, BxPc-3 and Panc-1. 72 hours post Hop-siRNA transfection, Hop expression 
was reduced in Clone #3, BxPc-3 and Panc-1 (Fig 5). Hop-siRNA did not alter levels 
of Hsp70 or Hsp90 expression in BxPc-3, Panc-1 and Clone #3 cell lines; however, 
the expression of the Hsp90 client proteins, HER2, Bcr-Abl, c-MET and v-Src were 
reduced with Hop-siRNA transfection (Fig 5). These results suggest that the effect of 
Hop knockdown in pancreatic cancer may be mediated through these proteins. 
 
3.6 Localisation of Hop membrane staining in pancreatic cancer tumours 
In a small panel of pancreatic tumours we identified cytoplasmic Hop expression in 
areas of tumour invasion and in necrotic cells in the epithelium of paraffin embedded 
pancreatic tumour specimens. Cytoplasmic Hop staining was also observed in the 
normal ductal and acinar cells of the exocrine pancreas but at a lesser intensity 
compared to tumour [17]. To explore Hop as a potential target for invasive pancreatic 
cancer, we studied the profile of 17 pancreatic tumours, 15 invasive/metastatic 
pancreatic ductal adenocarcinomas (PDACs), 1 cholangiocarcinoma and 1 intraductal 
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papillary mucinous neoplasm (IPMN).  All PDACs specimens displayed cytoplasmic 
Hop staining (Fig 6 A-B); in general stronger Hop staining was observed in higher 
PanIN than in lower PanIN grades. Fig 6A shows strong Hop staining in PanIN grade 
3 (arrow 1) compared to negligible staining in PanIN grade1 (arrow 2). The invasive 
front of the tumour also displayed strong Hop staining as shown in Fig 6B by 
perineural invasion. The nerve (arrow 1) is infiltrated by invasive pancreatic cells 
with high Hop expression (arrow 2). We also observed differential localised (sub-
nuclear and membrane) staining of Hop. In Fig 6C, linear sub-nuclear staining of Hop 
was seen in a PanIN grade1 tumour. Furthermore, membrane localisation of Hop was 
observed in an invasive pancreatic tumour with mucinous features (Fig 6D).  
 
4.0 Discussion 
Previously, protein identification by 2D DIGE followed by MALDI-TOF MS 
established a 2-fold increase in Hop expression in the more invasive pancreatic cancer 
cell line Clone #3 compared to Clone #8 (low invasion) [17]. In this study, we 
investigate the role of Hop in cancer cell invasion and its potential as a therapeutic 
target; we firstly provide evidence that Hop expression in pancreatic cancer cell lines 
corresponds to their invasive abilities. We show that Hop is involved in in vitro 
invasion in pancreatic cancer cell lines possibly through interaction with MMP-2. To 
our knowledge this is the first study implicating Hop in pancreatic cancer invasion via 
MMP-2. Eustace et al. [16] showed that Hsp90α chaperone-complex interactions are 
involved in MMP-2 activity and invasiveness in the fibrosarcoma cell line, HT-1080. 
Our work showed that loss of Hop after siRNA transfection reduced the invasiveness 
of BxPc-3 and Panc-1 cells; this decrease in invasion was mediated by a reduction in 
MMP-2 expression. The degradation of the extracellular matrix and connective tissue, 
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leading to tumour invasion and metastasis, is facilitated by MMPs [25]. MMPs are a 
family of proteinase enzymes requiring a zinc ion at their active site. MMPs are 
secreted extracellularly in a latent form and require activation for proteolytic activity. 
They are inhibited by specific tissue inhibitors of metalloproteinases (TIMPs) 
(reviewed in [26]). Gress et al. [27, 28] found that MMP-2 and MMP-9 may be 
involved in processes leading to the strong desmoplastic reaction - the deregulation of 
the extracellular matrix, including degradation and accumulation of dense fibrous 
tissue observed in pancreatic tumours. Hop was found in the CM of BxPc-3 and Panc-
1 suggesting that it may interact with MMP-2 extracellularly, also defined in other 
studies [21]. We showed further evidence for this interaction as MMP-2 co-
immunoprecipitated with Hop in BxPc-3 CM. Hsp90 also co-immunoprecipitated 
with Hop. Hsp90 expression in malignant cells has been reported to be constitutive, 
and intracellular levels are 2 to 10-fold higher compared to normal cells, suggesting a 
crucial role in survival and growth of cancer cells [29]. Using the specific Hsp90 
inhibitor, 17-AAG, we confirmed that inhibition of Hsp90 also decreased invasion via 
a decrease in MMP-2 and MMP-9 activation. This suggests a role for Hop in Hsp90-
mediated inhibition of invasion through extracellular interactions. Hop acts as a co-
chaperone in the Hsp90 chaperone cycle stabilising and activating a wide array of 
client proteins [30]. Having demonstrated that Hop knockdown resulted in decreased 
invasion through extracellular interaction with Hsp90 and MMP-2, we investigated 
whether siRNA knockdown of Hop could affect Hsp90-mediated client protein 
expression. Our study showed that Hop-siRNA mediated a decrease in levels of 
Hsp90 ‘client’ proteins; HER2, Bcr-Abl, c-MET and v-Src in pancreatic cancer cell 
lines. However, an important factor in the Hop-mediated Hsp90 inactivation could 
rely on whether the two proteins are complexed in the tumour cells. Kamal et al. [31] 
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determined that Hsp90 in tumour cells is present in multi-chaperone complexes and is 
engaged in active chaperoning. Co-immunoprecipitation of normal and tumour cell 
lysates with antibodies to Hsp90 revealed that more Hsp90 in tumour cells was 
present in complexes with co-chaperone proteins such as p23 and Hop compared to 
normal cells. Immunoprecipitation with antibodies to both p23 and Hop showed that 
the entire tumour cell pool of Hsp90 was present in complexes unlike normal cells. 
These results suggest that Hsp90 in tumour cells is in the form of multi-chaperone 
complexes which are actively engaged in chaperoning client oncoproteins. Therefore, 
Hop expression, through specific inhibition of the Hsp90-Hop complexes, survival 
pathways and MMP activation, could contribute to invasion in the pancreatic cancer 
cell lines, therefore making it a potentially valuable target for pancreatic cancer 
therapy.   
We cannot exclude the possibility that alteration of the Hsp90 pathway decreases 
invasion through interference with oncogenic signalling pathways. MET, a receptor 
for hepatoctye growth factor/scatter factor (HGF/SF) has been previously shown to 
play an important role in cancer invasion and metastasis [32]. As c-MET is a client of 
Hsp90, it is destabilised by the Hsp90 inhibitor, 17-AAG, which blocks reactivation 
of downstream signalling pathways (Akt Erk and/or STAT3) and EGFR family 
members [33]. Webb et al. [34] showed that geldanamycin (GA) down regulates MET 
expression at nanamolar concentrations, thus inhibiting HGF/SF-mediated cell 
motility and invasion. Another Hsp90 client protein, HER2 has been proposed to 
interact extracellularly with Hsp90 – activating HER2 by heterodimerisation with 
HER3, leading to actin remodelling and cell motility via activation of signal 
transduction pathways MAPK and PI3K-Akt [35, 36]. 
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The localisation of Hop in pancreatic cancer tumours and its secretion by cell lines 
may be of importance, as shown in other studies [21, 37], [9]. The mechanism of 
secreted Hop is poorly understood. Hop is secreted from fibrosarcoma cells [21] and 
from primary astrocyte cultures [9, 37]. Although Hop has been previously detected in 
the Golgi apparatus and small vesicles [38]; no transmembrane/signal peptide is 
contained within the Hop sequence. Therefore secretion of Hop may be through non-
classical secretory routes or through its membrane interactions with prion proteins 
[39]. To exclude the possibility of Hop expression in the media due to cell lysis at a 
low rate, recombinant Hop could be used to mimic extracellular secreted Hop and 
assess its function extracellularly. There is evidence to suggest that localisation of 
Hop may be due to phosphorylation. Hop can be phosphorylated by cell cycle kinases, 
phosphorylation by cdc2 (cell division cycle 2) kinase promotes cytoplasmic 
retention, whereas phosphorylation by casein kinase II (CKII) promotes nuclear Hop, 
suggesting that Hop might move between the cytoplasm and the nucleus under certain 
cell cycle conditions [40, 41]. The nuclear accumulation of Hop is primarily stress 
regulated and CKII phosphorylation has been shown not to disrupt Hop-Hsp90 
binding [36]. Longshaw et al. [42] reported that in the absence of Hop, soluble 
pYStat3 levels are decreased and accumulation of Stat3 occurs outside the nucleus in 
mESCs, suggesting that Hop facilitates phosphorylation and transport of Stat3 into the 
mESCs nucleus. 
Immunohistochemical analysis revealed a correlation between Hop expression and the 
degree of differentiation in PDAC tumours. The PanIN lesions show sequential 
changes in Hop expression levels from strong staining in high PanIN grades and 
invasive carcinoma compared to weak Hop staining in low PanIN grades. Differential 
Hop expression occurs at different stages of the malignant progression of PDAC, 
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suggesting a progressive increase in expression as the tumour becomes more 
malignant, possibly due to localisation of Hop resulting in nuclear/cytoplasmic or 
membrane accumulation of the protein.   
In summary, we have demonstrated for the first time that siRNAs specifically 
targeting human Hop substantially reduced the invasion of human pancreatic cancer 
cells in vitro through extracellular interactions with MMP-2 and Hsp90. Decreasing 
Hop levels by siRNA also degraded Hsp90 client proteins, HER2, Bcr-Abl, c-MET 
and v-Src possibly through Hsp90 inactivation. Targeting the Hsp90 pathway through 
Hop is an attractive strategy as multiple oncoproteins are dependent on this chaperone 
activity. Our results suggest that disruption of the Hop-Hsp90 complex may provide a 
novel mechanism for Hsp90 dependent pathways in pancreatic cancer. Recently, 
Horibe et al. [43] designed a novel peptide which disrupts the interaction between 
Hsp90 and the TPR2A binding domain of Hop. This specific inhibitor of Hsp90-Hop 
interaction showed selective antitumour activity, discriminating between normal and 
cancerous cell lines. Cells treated with the inhibitor exhibited loss of Hsp90-client 
proteins, survivin, CDK4 and Akt. Antitumour activity was also observed in vivo in a 
xenograft model of human pancreatic cancer in mice. 
 The differential localisation of Hop in invasive pancreatic tumours is interesting and 
further work into the significance of this observation is required in a larger panel of 
pancreatic cancer specimens and additional confocal analysis in cell lines. 
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Figure legends 
 
Figure 1. Hop protein expression in human pancreatic cancer cells. A.  
Representative Western immunoblot showing the expression of constitutive Hop in a 
panel of pancreatic cancer cell lines. Housekeeping gene β-actin was used as an 
internal control. B. Densitometry analysis of Hop bands (normalised to β-actin). Error 
bars represent the standard deviation of triplicate experiments. C. The invasive 
capacity of panel of cell lines. The total number of invading cells was determined by 
counting the number of cells per field in 10 random fields, at 200× magnification. The 
average number of cells per field was then multiplied by a factor of 140 (growth area 
of membrane/field area viewed at 200× magnification (calibrated using a microscope 
graticule)). Error bars represent the standard deviation of triplicate invasion assay 
experiments (n=3). 
Figure 2. Knockdown of Hop reduces the invasion of Panc-1 and BxPc-3 cells. A. 
Panc-1 and B. BxPc-3 cells were transfected with non-targeting scrambled siRNA 
(control siRNA) and three independent siRNA sequences against Hop. The total 
number of invading cells was determined by counting the number of cells per field in 
10 random fields, at 200× magnification. The average number of cells per field was 
then multiplied by a factor of 140 (growth area of membrane/field area viewed at 
200× magnification (calibrated using a microscope graticule)). Error bars represent 
the standard deviation of triplicate invasion assay experiments (n=3). 
Figure 3. Hop as an extracellular protein can disrupt MMP-2 expression            
A. Serum-free conditioned media from Panc-1 and BxPc-3 cells was collected, 
concentrated and immunoblotted for Hop B. Panc-1 and BxPc-3 cells transfected with 
Hop-siRNA (2) and (3) were immunoblotted for MMP-2.  
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Figure 4. Hop co-immunoprecipitates with Hsp90 and MMP-2 A. Hop was 
immunoprecipitated from BxPc-3 conditioned media as described in materials and 
methods. Proteins were detected by MMP-2 and Hsp90 antibodies as indicated (right 
side of panel). B. Effect of 17-AAG on pancreatic cancer To validate Hop as an 
inhibitor of invasion in the Hsp90-complex, we used the Hsp90 pharmacological 
inhibitor 17-AAG and observed its effect on MMP-2 and MMP-9 expression. BxPc-3 
cells were treated with 0.1 µM and 1 µM of 17-AAG for 24hrs under serum-free 
conditions. Conditioned medium was collected and MMP-2 and MMP-9 activities 
were analysed by gelatin zymography. C. Representative invasion assay pictures of 
cells invaded through Boyden invasion chambers (8 μm pore size) coated with 
Matrigel basement membrane matrix stained with 0.25% (w/v) crystal violet under 
control conditions and 24 hr treatment with 1 µM 17-AAG in Panc-1 and BxPc-3 
cells. Magnification 200×, scale bar 200 µm D. Invasion potential of Panc-1 and 
BxPc-3 cells treated with 1 µM 17-AAG as outlined in materials and methods. Graphs 
represented as the total number of invading cells, as determined by counting the 
number of cells per field in 10 random fields, at 200× magnification. The average 
number of cells per field was then multiplied by a factor of 140 (growth area of 
membrane/field area viewed at 200× magnification (calibrated using a microscope 
graticule)). Values are mean  standard deviation (n=3). 
Figure 5. Effect of Hop knockdown by siRNA on Hsp90 client proteins in BxPc-
3, Panc-1 and Clone #3. Pancreatic cancer cells were transfected with three 
independent siRNAs against Hop and the scrambled control siRNA. 72 hrs post 
transfection, the constitutive levels of Hop, Hsp90, Hsp70, HER2, Bcr-Abl, c-MET 
and v-Src were assayed by Western immunoblot. 
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Figure 6. Differential localisation of Hop in invasive pancreatic tumors A. PanIN 
grade 3 (arrow 1) displaying strong cytoplasmic Hop staining compared to PanIN 
grade 1 showing no Hop expression (arrow 2) B. Perineural invasion in PDAC, cancer 
cells invading around the nerve (arrow 1) stained strongly for Hop (arrow 2) C. PanIN 
grade 1 PDAC displaying sub-nuclear accumulation of Hop D. Invasive mucinous 
tumour displaying strong Hop complete membrane staining Magnification 200 ×.  
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